Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2026)

Foghorn Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 35.29% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $7.8 million (down 35.86% YoY), while the FY2025 annual figure was $8.7 million, down 26.51% from the prior year.
• Interest & Investment Income was $1.7 million for Q1 2026 at Foghorn Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $3.5 million in Q3 2024 to a low of $235000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.3 million across 5 years, with a median of $2.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 1035.74% in 2023, then plunged 44.7% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $2.4 million in 2022, then climbed by 11.95% to $2.7 million in 2023, then advanced by 16.39% to $3.1 million in 2024, then slumped by 44.7% to $1.7 million in 2025, then advanced by 1.75% to $1.7 million in 2026.
• The last three Interest & Investment Income figures came in at $1.7 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.